share_log
Reuters ·  Apr 25 08:00
Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of Ctx-009 in Combination With Paclitaxel for the Treatment of Patients With Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment